On April 14, 2026 EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2 costimulation, reported that new data highlighting its novel EVOLVE T cell engager platform will be presented at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting. The conference is being held April 17-22, 2026, in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the company’s presentations at the AACR (Free AACR Whitepaper) conference are as follows:
Oral Minisymposium Presentation #4055:
Title: Integrated CD2-costimulation on CD3 T cell engager EVOLVE platform yields differentiated and superior T cell effector profile
Presenting Author: Emma Stewart, Ph.D., EvolveImmune Therapeutics
Session Title: Advances in Therapeutic Antibodies
Session Date/Time: Monday, April 20, 2026, 2:30 – 4:30 p.m. PT
Location: Ballroom 20 CD – Upper Level – Convention Center
Poster Presentation #CT079:
Title: EIU-104101: A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T cell engager, in advanced urothelial and squamous cell carcinomas
Presenting Author: Tony Fiorino, M.D., Ph.D., EvolveImmune Therapeutics
Session Title: Phase I Clinical Trials in Progress
Session Date/Time: Monday, April 20, 2026, 9:00 a.m. – 12:00 p.m. PT
Location: Poster Section 51; Poster Board #10
Poster Presentation #5594:
Title: Pharmacological integration of CD3 and CD2 signaling triggers formation of a CD2 corolla that boosts T cell activation
Presenting Author: Sergio Trombetta, Ph.D., EvolveImmune Therapeutics
Session Title: T Cell Engagers 2/Antibody-Drug Conjugates 1
Session Date/Time: Tuesday, April 21, 2026, 2:00 – 5:00 p.m. PT
Location: Poster Section 8; Poster Board #13
About EVOLVE104
EVOLVE104 is a next-generation trispecific T cell engager that binds CD3 and CD2 on T cells and the tumor-associated antigens ULBP2/5/6, which have limited expression in normal human tissues and are found on a number of epithelial-derived malignancies, including urothelial carcinoma and a broad array of squamous cell carcinomas. In preclinical studies, EVOLVE104 has demonstrated compelling single-agent activity and combination activity with anti-PD-1 therapy, the ability to reinvigorate dysfunctional T cells, and a promising safety profile. EVOLVE104 is currently being studied in a first-in-human phase 1 clinical trial in subjects with advanced, relapsed or refractory solid tumors (NCT07217171).
(Press release, EvolveImmune Therapeutics, APR 14, 2026, View Source [SID1234664388])